| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2022 | BCRX Biocryst Pharmaceuticals Inc | Thackray Helen M.78 | Chief R&D Officer | Sell | 7,600 | $16.20 | $123,120.00 | -5.3% | -36.2% | -49.7% | |
| Apr 1, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 165,376 | $292.38 | $48,352,780.75 | - | +11.2% | +18.4% | |
| Apr 1, 2022 | NBIX Neurocrine Biosciences Inc | Rastetter William H48 | Director | Sell | 10,728 | $94.93 | $1,018,366.13 | -24.0% | +2.0% | +5.9% | |
| Apr 1, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $36.69 | $18,344.72 | -0.3% | -7.0% | +0.2% | |
| Mar 30, 2022 | LNTH Lantheus Holdings, Inc. | Walker Carol | Senior Vice President, Quality | Sell | 15,000 | $56.22 | $843,300.00 | -18.8% | +14.1% | +44.4% | |
| Mar 30, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 2,500 | $292.03 | $730,075.00 | - | +9.9% | +18.6% | |
| Mar 29, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 4,341 | $292.39 | $1,269,253.89 | - | +13.9% | +17.6% | |
| Mar 28, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 20,000 | $0.28 | $5,600.00 | - | - | - | |
| Mar 28, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 7,538 | $292.16 | $2,202,264.39 | - | +12.6% | +16.9% | |
| Mar 25, 2022 | TSNDF Terrascend Corp. | Jw Asset Management, LLC65 | Executive Chairman | Sell | 4,764 | $5.40 | $25,725.60 | - | - | - | |
| Mar 25, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 45,000 | $0.25 | $11,283.00 | - | - | - | |
| Mar 24, 2022 | IRWD Ironwood Pharmaceuticals Inc | Silver Ronald68 | Principal Accounting Officer | Sell | 3,031 | $12.75 | $38,645.25 | -2.8% | -12.2% | -16.2% | |
| Mar 22, 2022 | TSNDF Terrascend Corp. | Jw Asset Management, LLC65 | Executive Chairman | Buy | 10,000 | $5.52 | $55,200.00 | - | - | - | |
| Mar 22, 2022 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 8,755 | $95.05 | $832,156.21 | -11.5% | -1.5% | +0.4% | |
| Mar 21, 2022 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 7,253 | $72.67 | $527,075.51 | -24.6% | -27.0% | -44.5% | |
| Mar 21, 2022 | ANIP Ani Pharmaceuticals Inc | Walsh Patrick D52 | Director | Buy | 5,000 | $27.76 | $138,794.00 | +10.3% | -7.0% | +48.0% | |
| Mar 21, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 35,245 | $292.43 | $10,306,604.11 | - | +3.0% | +15.4% | |
| Mar 21, 2022 | TSNDF Terrascend Corp. | Jw Asset Management, LLC65 | Executive Chairman | Buy | 230,000 | $5.60 | $1,287,100.00 | +0.1% | - | - | |
| Mar 21, 2022 | ANIP Ani Pharmaceuticals Inc | Lalwani Nikhil66 | President &CEO | Buy | 7,224 | $27.69 | $199,997.16 | +4.4% | -7.0% | +48.0% | |
| Mar 21, 2022 | BMY Bristol Myers Squibb Co | Caforio Giovanni59 | Board Chair And CEO | Sell | 25,000 | $71.52 | $1,788,000.00 | -4.1% | +8.4% | -2.9% | |
| Mar 21, 2022 | TSNDF Terrascend Corp. | Schutter Edward J | Director | Buy | 180,000 | $5.59 | $1,006,200.00 | +17.0% | - | - | |
| Mar 21, 2022 | ANIP Ani Pharmaceuticals Inc | Gassert Chad60 | SVP - Corp. Dev. &Strategy | Buy | 10,000 | $27.51 | $275,086.50 | +1.3% | -7.0% | +48.0% | |
| Mar 18, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $288.18 | $60,518,363.05 | - | +0.5% | +15.5% | |
| Mar 17, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,000 | $283.80 | $62,435,452.82 | - | +3.0% | +16.4% | |
| Mar 17, 2022 | JNJ Johnson & Johnson | Mongon Thibaut | Exec VP, Ww Chair, Consumer | Sell | 23,681 | $176.25 | $4,173,718.47 | -4.7% | -3.2% | -12.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.